Zura Bio ZURA 深 沪
等待开盘 05-20 09:30:00 美东时间
3.99
-0.130
-3.16%
华盛通- 最 高4.28
- 今 开4.12
- 成交量 64.96万股
- 最 低 3.98
- 昨 收 4.12
- 总市值 37.90万
- 52周最高 7.44
- 市盈率 静 --
- 换手率 0.68%
- 52周最低 0.98
- 委 比 4.26%
- 总股本 9.50万
- 历史最高 37.55
- 量 比 1.43
- 振 幅 7.28%
- 历史最低 0.97
- 每 手 1
- 风险率 1.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zura Bio grants Chief Business Officer option for 600,000 shares at $4.8###
Zura Bio grants Chief Business Officer option for 600,000 shares at $4.8### Zura Bio granted Chief Business Officer Muzammil Mustufa an inducement stock option for 600,000 Class A ordinary shares, with grant date May 13, 2026. Exercise price set at USD 4.8 per share, matching closing price on May 13
05-14 19:30
Zura Bio Q1 EPS $(0.22) Misses $(0.18) Estimate
Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.18) by 22.22 percent. This is a 15.79 percent decrease over losses of $(0.19) per share from the
05-07 20:56
AST SpaceMobile, SBC Medical Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures fall around 250 points on Monday. ASTS shares drop 13.5% after satellite placed in lower-than-planned orbit. Other stocks decline in pre-market trading.
04-20 20:02
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
Oppenheimer Maintains Outperform on Zura Bio, Lowers Price Target to $15
Oppenheimer analyst Justin Kim maintains Zura Bio (NASDAQ:ZURA) with a Outperform and lowers the price target from $16 to $15.
03-20 23:02
Zura Bio Q4 EPS $(0.49) Misses $(0.22) Estimate
Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.22) by 122.73 percent. This is a 133.33 percent decrease over losses of $(0.21) per share from the
03-20 04:31
Zura Bio Says Design Of Its Ongoing Phase 2 TibuSURE Clinical Trial Evaluating Tibulizumab In SSc Accepted For Presentation At Systemic Sclerosis World Congress
Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and
03-05 19:39
Zura Bio to Present Phase 2 TibuSURE Study Design Poster at 9th Systemic Sclerosis World Congress
Zura Bio to Present Phase 2 TibuSURE Study Design Poster at 9th Systemic Sclerosis World Congress Zura Bio Ltd. will attend the 9th Systemic Sclerosis World Congress in Athens, Greece, March 5–7, 2026, where it will present a poster on the Phase 2 TibuSURE trial design evaluating tibulizumab (ZB-106
03-05 19:30
BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes opened higher on Wednesday after volatile sessions ear
02-25 22:39
Zura Bio prices $125M public offering
Zura Bio Limited (ZURA) priced an underwritten public offering of 18.2M Class A ordinary shares at $6.25/share. The company is also offering 1.8M pre-funded warrants at $6.249 each, reflecting the $6....
02-25 20:40
